Evaluation of clinical outcomes of vaccinated and unvaccinated patients with hospitalization for COVID-19.

IF 16.4 1区 化学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Yusuf Emre Ozdemir, Burak Kizilcay, Muge Sonmezisik, Muhammet Salih Tarhan, Deniz Borcak, Meryem Sahin Ozdemir, Osman Faruk Bayramlar, Zuhal Yesilbag, Sevtap Senoglu, Habip Gedik, Hayat Kumbasar Karaosmanoglu, Kadriye Kart Yasar
{"title":"Evaluation of clinical outcomes of vaccinated and unvaccinated patients with hospitalization for COVID-19.","authors":"Yusuf Emre Ozdemir,&nbsp;Burak Kizilcay,&nbsp;Muge Sonmezisik,&nbsp;Muhammet Salih Tarhan,&nbsp;Deniz Borcak,&nbsp;Meryem Sahin Ozdemir,&nbsp;Osman Faruk Bayramlar,&nbsp;Zuhal Yesilbag,&nbsp;Sevtap Senoglu,&nbsp;Habip Gedik,&nbsp;Hayat Kumbasar Karaosmanoglu,&nbsp;Kadriye Kart Yasar","doi":"10.1556/030.2022.01860","DOIUrl":null,"url":null,"abstract":"<p><p>We aimed to compare vaccinated and unvaccinated patients hospitalized with COVID-19 in terms of disease severity, need for intensive care unit (ICU) admission, and death. In addition, we determined the factors affecting the COVID-19 severity in vaccinated patients. Patients aged 18-65 years who were hospitalized for COVID-19 between September and December 2021 were retrospectively analyzed in three groups: unvaccinated, partially vaccinated, and fully vaccinated.A total of 854 patients were included. Mean age was 47.9 ± 10.6 years, 474 patients (55.5%) were male. Of these, 230 patients (26.9%) were fully vaccinated, 97 (11.3%) were partially vaccinated, and 527 (61.7%) were unvaccinated. Of the fully vaccinated patients, 67% (n = 153) were vaccinated with CoronaVac and 33% (n = 77) were vaccinated with Pfizer-BioNTech. All patients (n = 97) with a single dose were vaccinated with Pfizer-BioNTech. One hundred thirteen (13.2%) patients were transferred to ICU. A hundred (11.7%) patients were intubated and 77 (9.0%) patients died. Advanced age (P = 0.028, 95% CI = 1.00-1.07, OR = 1.038) and higher Charlson Comorbidity Index (CCI) (P < 0.001, 95% CI = 1.20-1.69, OR = 1.425) were associated with increased mortality, while being fully vaccinated (P = 0.008, 95% CI = 0.23-0.80, OR = 0.435) was associated with survival in multivariate analysis. Full dose vaccination reduced the need for ICU admission by 49.7% (95% CI = 17-70) and mortality by 56.5% (95% CI = 20-77). When the fully vaccinated group was evaluated, we found that death was observed more frequent in patients with CCI>3 (19.1 vs 5.8%, P < 0.01, OR = 3.7). Therefore, the booster vaccine especially in individuals with comorbidities should not be delayed, since the survival expectation is low in patients with a high comorbidity index.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2022-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1556/030.2022.01860","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 2

Abstract

We aimed to compare vaccinated and unvaccinated patients hospitalized with COVID-19 in terms of disease severity, need for intensive care unit (ICU) admission, and death. In addition, we determined the factors affecting the COVID-19 severity in vaccinated patients. Patients aged 18-65 years who were hospitalized for COVID-19 between September and December 2021 were retrospectively analyzed in three groups: unvaccinated, partially vaccinated, and fully vaccinated.A total of 854 patients were included. Mean age was 47.9 ± 10.6 years, 474 patients (55.5%) were male. Of these, 230 patients (26.9%) were fully vaccinated, 97 (11.3%) were partially vaccinated, and 527 (61.7%) were unvaccinated. Of the fully vaccinated patients, 67% (n = 153) were vaccinated with CoronaVac and 33% (n = 77) were vaccinated with Pfizer-BioNTech. All patients (n = 97) with a single dose were vaccinated with Pfizer-BioNTech. One hundred thirteen (13.2%) patients were transferred to ICU. A hundred (11.7%) patients were intubated and 77 (9.0%) patients died. Advanced age (P = 0.028, 95% CI = 1.00-1.07, OR = 1.038) and higher Charlson Comorbidity Index (CCI) (P < 0.001, 95% CI = 1.20-1.69, OR = 1.425) were associated with increased mortality, while being fully vaccinated (P = 0.008, 95% CI = 0.23-0.80, OR = 0.435) was associated with survival in multivariate analysis. Full dose vaccination reduced the need for ICU admission by 49.7% (95% CI = 17-70) and mortality by 56.5% (95% CI = 20-77). When the fully vaccinated group was evaluated, we found that death was observed more frequent in patients with CCI>3 (19.1 vs 5.8%, P < 0.01, OR = 3.7). Therefore, the booster vaccine especially in individuals with comorbidities should not be delayed, since the survival expectation is low in patients with a high comorbidity index.

COVID-19住院患者接种疫苗与未接种疫苗临床结局评价
我们的目的是比较接种疫苗和未接种疫苗的COVID-19住院患者在疾病严重程度、重症监护病房(ICU)入院需求和死亡方面的差异。此外,我们确定了影响接种疫苗患者COVID-19严重程度的因素。回顾性分析2021年9月至12月期间因COVID-19住院的18-65岁患者,分为三组:未接种疫苗、部分接种疫苗和完全接种疫苗。共纳入854例患者。平均年龄47.9±10.6岁,男性474例,占55.5%。其中,230例(26.9%)完全接种疫苗,97例(11.3%)部分接种疫苗,527例(61.7%)未接种疫苗。在完全接种疫苗的患者中,67% (n = 153)接种了CoronaVac, 33% (n = 77)接种了Pfizer-BioNTech。所有患者(n = 97)均接种了单剂量辉瑞- biontech疫苗。113例(13.2%)患者转入ICU。100例(11.7%)患者插管,77例(9.0%)患者死亡。在多因素分析中,高龄(P = 0.028, 95% CI = 1.00-1.07, OR = 1.038)和较高的Charlson共病指数(CCI) (P < 0.001, 95% CI = 1.20-1.69, OR = 1.425)与死亡率增加相关,而完全接种疫苗(P = 0.008, 95% CI = 0.23-0.80, OR = 0.435)与生存率相关。全剂量疫苗接种使ICU住院需求降低了49.7% (95% CI = 17-70),死亡率降低了56.5% (95% CI = 20-77)。当对完全接种组进行评估时,我们发现CCI>3的患者死亡更频繁(19.1 vs 5.8%, P < 0.01, OR = 3.7)。因此,加强疫苗特别是对有合并症的个体不应延迟,因为合并症指数高的患者的生存预期较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Accounts of Chemical Research
Accounts of Chemical Research 化学-化学综合
CiteScore
31.40
自引率
1.10%
发文量
312
审稿时长
2 months
期刊介绍: Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信